Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action
2021 · European Journal of Immunology · 189 citations
https://doi.org/10.1002/eji.202048747
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
20
Papers
557
Citations
9
h-index
9
i10-index
Zena Willsmore is an academic researcher from King's College London. The author has contributed to research in topics: Immunotherapy and Immune Responses & Cancer Immunotherapy and Biomarkers & CAR-T cell therapy research. The author has an h-index of 9, co-authored 17 publications.
ORCID: 0000-0001-8750-804XClick to start Chat